Skip to main content

Advertisement

SpringerLink
Log in

Report of the JDS/JCA Joint Committee on Diabetes and Cancer

  • Report of the committee
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

In recent years, diabetes has been shown to be associated with cancer risk, and this has led to a joint committee being formed, enlisting experts from the Japan Diabetes Society (JDS) and the Japanese Cancer Association (JCA) to address this issue. Epidemiological data in Japan provides evidence to demonstrate that diabetes is associated with increased risk for cancers, especially colorectal, liver, and pancreatic cancers. The mechanisms through which diabetes is assumed to promote oncogenesis include insulin resistance and associated hyperinsulinemia, hyperglycemia and inflammation. Common risk factors for type 2 diabetes and cancer include aging, male sex, obesity, physical inactivity, inappropriate diet (excessive red/processed meat intake, inadequate vegetable/fruit/dietary fiber intake), excessive alcohol drinking, and smoking. Given that inappropriate diet/exercise, smoking and excessive alcohol drinking are common risk factors for diabetes and cancer, diet/exercise therapy, smoking cessation and alcohol moderation may be associated with decreased risk for cancer in diabetic patients. There is as yet limited evidence as to whether any particular anti-diabetic agents may influence cancer risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. Report of the Japan Diabetes Society/the Japanese Cancer Association Joint Committee on Diabetes and Cancer (in Japanese). J Japan Diabetes Soc. 2013;56(6):374–90.

    Google Scholar 

  2. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103–23.

    Article  PubMed  CAS  Google Scholar 

  3. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2056–62.

    Article  PubMed  Google Scholar 

  4. Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer. 2007;96(3):507–9.

    Article  PubMed  CAS  Google Scholar 

  5. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47(6):1071–8.

    Article  PubMed  CAS  Google Scholar 

  6. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995;273(20):1605–9.

    Article  PubMed  CAS  Google Scholar 

  7. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50(7):1365–74.

    Article  PubMed  CAS  Google Scholar 

  8. Huxley R, Ansary-Moghaddam A, de Gonzalez AB, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(11):2076–83.

    Article  PubMed  CAS  Google Scholar 

  9. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(22):1679–87.

    Article  PubMed  Google Scholar 

  10. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 2006;49(12):2819–23.

    Article  PubMed  CAS  Google Scholar 

  11. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121(4):856–62.

    Article  PubMed  CAS  Google Scholar 

  12. Mitri J, Castillo J, Pittas AG. Diabetes and risk of non-Hodgkin’s lymphoma. Diabetes Care. 2008;31(12):2391–7.

    Article  PubMed  Google Scholar 

  13. Noto H, Osame K, Sasazuki T, Noda M. Substantially increased risk of cancer in patients with diabetes mellitus A systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complicat. 2010;24(5):345–53.

    Article  PubMed  Google Scholar 

  14. Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocr Pract. 2011;17(4):616–28.

    Article  PubMed  Google Scholar 

  15. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60(4):207–21.

    Article  PubMed  Google Scholar 

  16. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–85.

    Article  PubMed  Google Scholar 

  17. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166(17):1871–7.

    Article  PubMed  Google Scholar 

  18. Inoue M, Noda M, Kurahashi N, Iwasaki M, Sasazuki S, Iso H, Tsugane S. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev. 2009;18(3):240–7.

    Article  PubMed  Google Scholar 

  19. Inoue M, Kurahashi N, Iwasaki M, Tanaka Y, Mizokami M, Noda M, Tsugane S. Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). Cancer Causes Control. 2009;20(5):741–50.

    Article  PubMed  Google Scholar 

  20. Noto H, Tsujimoto T, Noda M. Significantly increased risk of cancer in diabetes mellitus patients: a meta-analysis of epidemiological evidence in Asians and non-Asians. J Diabetes Invest. 2012;3(1):24–33.

    Article  Google Scholar 

  21. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4(3):369–80.

    Article  PubMed  Google Scholar 

  22. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300(23):2754–64.

    Article  PubMed  CAS  Google Scholar 

  23. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care. 2010;33(4):931–9.

    Article  PubMed  Google Scholar 

  24. Yoon JM, Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes mellitus increases the risk of gastric cancer: a meta-analysis. World J Gastroenterol. 2013;19(6):936–45.

    Article  PubMed  Google Scholar 

  25. Center for Cancer Control and Information Services, National Cancer Center, Japan; 2013. http://ganjoho.jp/data/professional/statistics/backnumber/2012/fig10.pdf. Accessed 31 May 2013.

  26. Center for Cancer Control and Information Services, National Cancer Center, Japan; 2013. http://ganjoho.jp/data/professional/statistics/odjrh3000000hwsa-att/mcij2007_report.pdf. Accessed 31 May 2013.

  27. Ogawa W, Kasuga M. Mechanism of insulin action and diabetes mellitus. Seikagaku. 2003;75(10):1332–44 (in Japanese).

    PubMed  CAS  Google Scholar 

  28. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.

    Article  PubMed  CAS  Google Scholar 

  29. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi PA, Molinolo AA, Kurshan N, Mejia W, Santopietro S, Yakar S, Wood TL, LeRoith D. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res. 2010;70(2):741–51.

    Article  PubMed  CAS  Google Scholar 

  30. Gogg S, Smith U, Jansson PA. Increased MAPK activation and impaired insulin signaling in subcutaneous microvascular endothelial cells in type 2 diabetes: the role of endothelin-1. Diabetes. 2009;58(10):2238–45.

    Article  PubMed  CAS  Google Scholar 

  31. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab. 2006;17(8):328–36.

    Article  PubMed  CAS  Google Scholar 

  32. Nakae J, Kido Y, Accili D. Distinct and overlapping functions of insulin and IGF-1 receptors. Endocr Rev. 2001;22(6):818–35.

    Article  PubMed  CAS  Google Scholar 

  33. Sung MK, Yeon JY, Park SY, Park JH, Choi MS. Obesity-induced metabolic stresses in breast and colon cancer. Ann N Y Acad Sci. 2011;1229:61–8.

    Article  PubMed  CAS  Google Scholar 

  34. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354(3):270–82.

    Article  PubMed  CAS  Google Scholar 

  35. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91.

    Article  PubMed  CAS  Google Scholar 

  36. Dandona P, Dhindsa S. Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab. 2011;96(9):2643–51.

    Article  PubMed  CAS  Google Scholar 

  37. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, Kahn CR. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000;289(5487):2122–5.

    Article  PubMed  CAS  Google Scholar 

  38. Chang YC, Chuang LM. The role of oxidative stress in the pathogenesis of type 2 diabetes: from molecular mechanism to clinical implication. Am J Transl Res. 2010;2(3):316–31.

    PubMed  CAS  Google Scholar 

  39. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–70.

    Article  PubMed  CAS  Google Scholar 

  40. Akatsuka S, Toyokuni S. Genome-wide assessment of oxidatively generated DNA damage. Free Radic Res. 2012;46(4):523–30.

    Article  PubMed  CAS  Google Scholar 

  41. Ohsawa S, Sato Y, Enomoto M, Nakamura M, Betsumiya A, Igaki T. Mitochondrial defect drives non-autonomous tumour progression through Hippo signalling in Drosophila. Nature. 2012;490(7421):547–51.

    Article  PubMed  CAS  Google Scholar 

  42. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85–95.

    Article  PubMed  CAS  Google Scholar 

  43. Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol. 2010;299(1):F14–25.

    Article  PubMed  CAS  Google Scholar 

  44. Pirola L, Balcerczyk A, Okabe J, El-Osta A. Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol. 2010;6(12):665–75.

    Article  PubMed  CAS  Google Scholar 

  45. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12–27.

    Article  PubMed  CAS  Google Scholar 

  46. Meng D, Mei A, Liu J, Kang X, Shi X, Qian R, Chen S. NADPH oxidase 4 mediates insulin-stimulated HIF-1alpha and VEGF expression, and angiogenesis in vitro. PLoS ONE. 2012;7(10):e48393.

    Article  PubMed  CAS  Google Scholar 

  47. de Heredia FP, Gomez-Martinez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc. 2012;71(2):332–8.

    Article  PubMed  CAS  Google Scholar 

  48. Bondia-Pons I, Ryan L, Martinez JA. Oxidative stress and inflammation interactions in human obesity. J Physiol Biochem. 2012;68(4):701–11.

    Article  PubMed  CAS  Google Scholar 

  49. Back SH, Kaufman RJ. Endoplasmic reticulum stress and type 2 diabetes. Annu Rev Biochem. 2012;81:767–93.

    Article  PubMed  CAS  Google Scholar 

  50. Flamment M, Hajduch E, Ferre P, Foufelle F. New insights into ER stress-induced insulin resistance. Trends Endocrinol Metab. 2012;23(8):381–90.

    Article  PubMed  CAS  Google Scholar 

  51. Garg AD, Kaczmarek A, Krysko O, Vandenabeele P, Krysko DV, Agostinis P. ER stress-induced inflammation: does it aid or impede disease progression? Trends Mol Med. 2012;18(10):589–98.

    Article  PubMed  CAS  Google Scholar 

  52. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99.

    Article  PubMed  CAS  Google Scholar 

  53. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23(5):599–622.

    Article  PubMed  CAS  Google Scholar 

  54. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol. 2011;12(8):715–23.

    Article  PubMed  CAS  Google Scholar 

  55. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 2013;17(2):185–96.

    Article  PubMed  CAS  Google Scholar 

  56. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33(4):547–94.

    Article  PubMed  CAS  Google Scholar 

  57. Villarreal-Molina MT, Antuna-Puente B. Adiponectin: anti-inflammatory and cardioprotective effects. Biochimie. 2012;94(10):2143–9.

    Article  PubMed  CAS  Google Scholar 

  58. Park J, Scherer PE. Leptin and cancer: from cancer stem cells to metastasis. Endocr Relat Cancer. 2011;18(4):C25–9.

    Article  PubMed  CAS  Google Scholar 

  59. Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA. Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control. 2012;23(7):991–1008.

    Article  PubMed  Google Scholar 

  60. Ministry of Health, Labour and Welfare, Japan; 2013. http://www.mhlw.go.jp/stf/houdou/2r98520000020qbb-att/2r98520000021c0o.pdf. Accessed 31 May 2013.

  61. Center for Cancer Control and Information Services, National Cancer Center, Japan; 2013. http://ganjoho.jp/public/statistics/pub/statistics02.html. Accessed 31 May 2013.

  62. van Dam RM, Hu FB. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA. 2005;294(1):97–104.

    Article  PubMed  Google Scholar 

  63. Yu X, Bao Z, Zou J, Dong J. Coffee consumption and risk of cancers: a meta-analysis of cohort studies. BMC Cancer. 2011;11:96.

    Article  PubMed  Google Scholar 

  64. Japan Diabetes Society. Evidence-based Practice Guideline for the Treatment of Diabetes in Japan 2010. Tokyo: Nankodo; 2010 (in Japanese).

    Google Scholar 

  65. American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care 2012;35 Suppl 1:S11–63.

    Google Scholar 

  66. World Health Organization International Agency for Research on Cancer. Weight control and physical activity. Lyon: IARC Press; 2002.

  67. Tsugane S. The development and evaluation of cancer prevention strategies in Japan. 2011 Research report. The third-term comprehensive control research for cancer. Ministry of Health, Labour and Welfare (in Japanese).

  68. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.

    Article  PubMed  Google Scholar 

  69. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, Lamonte MJ, Stroup AM, Hunt SC. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753–61.

    Article  PubMed  CAS  Google Scholar 

  70. Inoue M, Sobue T, Tsugane S. Impact of body mass index on the risk of total cancer incidence and mortality among middle-aged Japanese: data from a large-scale population-based cohort study–the JPHC study. Cancer Causes Control. 2004;15(7):671–80.

    Article  PubMed  Google Scholar 

  71. Barclay AW, Petocz P, McMillan-Price J, Flood VM, Prvan T, Mitchell P, Brand-Miller JC. Glycemic index, glycemic load, and chronic disease risk–a meta-analysis of observational studies. Am J Clin Nutr. 2008;87(3):627–37.

    PubMed  CAS  Google Scholar 

  72. Kushi LH, Byers T, Doyle C, Bandera EV, McCullough M, McTiernan A, Gansler T, Andrews KS, Thun MJ. American Cancer Society N, Physical Activity Guidelines Advisory C. American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2006;56(5):254–81.

    Article  PubMed  Google Scholar 

  73. Kastorini CM, Panagiotakos DB. Dietary patterns and prevention of type 2 diabetes: from research to clinical practice; a systematic review. Curr Diabetes Rev. 2009;5(4):221–7.

    Article  PubMed  CAS  Google Scholar 

  74. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr. 2002;132(11 Suppl):3456S–64S.

    PubMed  CAS  Google Scholar 

  75. Lee IM. Physical activity and cancer prevention–data from epidemiologic studies. Med Sci Sports Exerc. 2003;35(11):1823–7.

    Article  PubMed  Google Scholar 

  76. Inoue M, Yamamoto S, Kurahashi N, Iwasaki M, Sasazuki S, Tsugane S. Daily total physical activity level and total cancer risk in men and women: results from a large-scale population-based cohort study in Japan. Am J Epidemiol. 2008;168(4):391–403.

    Article  PubMed  Google Scholar 

  77. Jeon CY, Lokken RP, Hu FB, van Dam RM. Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review. Diabetes Care. 2007;30(3):744–52.

    Article  PubMed  Google Scholar 

  78. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537–44.

    Article  PubMed  CAS  Google Scholar 

  79. World Health Organization International Agency for Research on Cancer. Tobacco smoke and involuntary smoking. Lyon: IARC Press; 2004.

    Google Scholar 

  80. World Health Organization International Agency for Research on Cancer. Smokeless tobacco and some tobacco-specific N-nitrosamines. Lyon: IARC Press; 2007.

    Google Scholar 

  81. Foy CG, Bell RA, Farmer DF, Goff DC Jr, Wagenknecht LE. Smoking and incidence of diabetes among U.S. adults: findings from the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2005;28(10):2501–7.

    Article  PubMed  Google Scholar 

  82. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2007;298(22):2654–64.

    Article  PubMed  CAS  Google Scholar 

  83. Oba S, Noda M, Waki K, Nanri A, Kato M, Takahashi Y, Poudel-Tandukar K, Matsushita Y, Inoue M, Mizoue T, Tsugane S, Fadini GP. Smoking cessation increases short-term risk of type 2 diabetes irrespective of weight gain: the Japan Public Health Center-Based Prospective Study. PLoS ONE. 2012;7(2):e17061.

    Article  PubMed  CAS  Google Scholar 

  84. Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V, Group WHOIAfRoCMW. A review of human carcinogens—part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009;10(11):1033–4.

    Article  PubMed  Google Scholar 

  85. Inoue M, Wakai K, Nagata C, Mizoue T, Tanaka K, Tsuji I, Tsugane S. Alcohol drinking and total cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2007;37(9):692–700.

    Article  PubMed  Google Scholar 

  86. World Health Organization International Agency for Research on Cancer. Alcohol consumption and ethyl carbamate. Lyon: IARC Press; 2010.

    Google Scholar 

  87. Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Inter Med. 2004;140(3):211–9.

    Article  Google Scholar 

  88. Baliunas DO, Taylor BJ, Irving H, Roerecke M, Patra J, Mohapatra S, Rehm J. Alcohol as a risk factor for type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2009;32(11):2123–32.

    Article  PubMed  CAS  Google Scholar 

  89. Seike N, Noda M, Kadowaki T. Alcohol consumption and risk of type 2 diabetes mellitus in Japanese: a systematic review. Asia Pac J Clin Nutr. 2008;17(4):545–51.

    PubMed  Google Scholar 

  90. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140(2):197–208.

    Article  PubMed  CAS  Google Scholar 

  91. Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. Int J Biol Sci. 2011;7(7):1003–15.

    Article  PubMed  CAS  Google Scholar 

  92. Itoh M, Suganami T, Nakagawa N, Tanaka M, Yamamoto Y, Kamei Y, Terai S, Sakaida I, Ogawa Y. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. Am J Pathol. 2011;179(5):2454–63.

    Article  PubMed  CAS  Google Scholar 

  93. Minamino T, Orimo M, Shimizu I, Kunieda T, Yokoyama M, Ito T, Nojima A, Nabetani A, Oike Y, Matsubara H, Ishikawa F, Komuro I. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med. 2009;15(9):1082–7.

    Article  PubMed  CAS  Google Scholar 

  94. Gonzalez-Rodriguez A, Mas-Gutierrez JA, Mirasierra M, Fernandez-Perez A, Lee YJ, Ko HJ, Kim JK, Romanos E, Carrascosa JM, Ros M, Vallejo M, Rondinone CM, Valverde AM. Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging. Aging Cell. 2012;11(2):284–96.

    Article  PubMed  CAS  Google Scholar 

  95. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, Sawicki PT. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52(9):1732–44.

    Article  PubMed  CAS  Google Scholar 

  96. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia. 2009;52(9):1745–54.

    Article  PubMed  CAS  Google Scholar 

  97. Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52(9):1755–65.

    Article  PubMed  CAS  Google Scholar 

  98. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766–77.

    Article  PubMed  CAS  Google Scholar 

  99. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia. 2012;55(1):51–62.

    Article  PubMed  CAS  Google Scholar 

  100. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28.

    Article  CAS  Google Scholar 

  101. Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, Gin H, Le Jeunne C, Pariente A, Droz C, Moore N. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia. 2012;55(3):644–53.

    Article  PubMed  CAS  Google Scholar 

  102. Fagot JP, Blotiere PO, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk of cancer compared with other basal insulins? A French nationwide cohort study based on national administrative databases. Diabetes Care. 2013;36(2):294–301.

    Article  PubMed  CAS  Google Scholar 

  103. Yang X, Ko GT, So WY, Ma RC, Yu LW, Kong AP, Zhao H, Chow CC, Tong PC, Chan JC. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes. 2010;59(5):1254–60.

    Article  PubMed  CAS  Google Scholar 

  104. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia. 2011;54(8):2009–15.

    Article  PubMed  Google Scholar 

  105. Yang X, So WY, Ma RC, Yu LW, Ko GT, Kong AP, Ng VW, Luk AO, Ozaki R, Tong PC, Chow CC, Chan JC. Use of sulphonylurea and cancer in type 2 diabetes—the Hong Kong Diabetes Registry. Diabetes Res Clin Pract. 2010;90(3):343–51.

    Article  PubMed  CAS  Google Scholar 

  106. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012;2012:413782.

    Article  PubMed  CAS  Google Scholar 

  107. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case–control study. Acta Diabetol. 2009;46(4):279–84.

    Article  PubMed  CAS  Google Scholar 

  108. United States Food and Drug Administration; 2013. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=751747da-7c1f-41ad-b1a6-a6d920f70599. Accessed 31 May 2013.

  109. United States Food and Drug Administration; 2013. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4. Accessed 31 May 2013.

  110. Pharmaceuticals and Medical Devices Agency, Japan; 2013. http://www.info.pmda.go.jp/go/pack/2499411G1026_2_01/. Accessed 31 May 2013.

  111. Pharmaceuticals and Medical Devices Agency, Japan; 2013. http://www.info.pmda.go.jp/go/pack/2499410G1021_1_05/. Accessed 31 May 2013.

  112. Pharmaceuticals and Medical Devices Agency, Japan; 2013. http://www.info.pmda.go.jp/go/pack/3969010F1034_2_12/. Accessed 31 May 2013.

  113. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150–6.

    Article  PubMed  CAS  Google Scholar 

  114. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27(Suppl 3):57–64.

    Article  PubMed  CAS  Google Scholar 

  115. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89.

    Article  PubMed  CAS  Google Scholar 

  116. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34(6):1369–71.

    Article  PubMed  Google Scholar 

  117. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34(4):916–22.

    Article  PubMed  CAS  Google Scholar 

  118. Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, Suissa S. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case–control study. BMJ. 2012;344:e3645.

    Article  PubMed  Google Scholar 

  119. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55(7):1953–62.

    Article  PubMed  CAS  Google Scholar 

  120. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012;35(2):278–80.

    Article  PubMed  CAS  Google Scholar 

  121. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ. 2012;184(12):E675–83.

    Article  PubMed  Google Scholar 

  122. Pharmaceuticals and Medical Devices Agency, Japan; 2013. http://www.info.pmda.go.jp/go/pack/3969007F1024_1_29/. Accessed 31 May 2013.

  123. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE. 2012;7(3):e33411.

    Article  PubMed  CAS  Google Scholar 

  124. Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, Crowe FL, Farmer AJ, Harrison S, Hirst JA, Home P, Kahn SE, McLellan JH, Perera R, Pluddemann A, Ramachandran A, Roberts NW, Rose PW, Schweizer A, Viberti G, Holman RR. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia. 2012;55(10):2593–603.

    Article  PubMed  CAS  Google Scholar 

  125. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012;35(12):2665–73.

    Article  PubMed  CAS  Google Scholar 

  126. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci. 2012;122(6):253–70.

    Article  PubMed  CAS  Google Scholar 

  127. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;67(22):10804–12.

    Article  PubMed  CAS  Google Scholar 

  128. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol. 2012;29(2):1314–27.

    Article  PubMed  CAS  Google Scholar 

  129. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12(1):65–82.

    Article  PubMed  CAS  Google Scholar 

  130. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R, Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

    Article  PubMed  CAS  Google Scholar 

  131. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602–12.

    Article  PubMed  CAS  Google Scholar 

  132. Ministry of Health, Labour and Welfare, Japan; 2013. http://www.mhlw.go.jp/bunya/kenkou/dl/gan_kenshin01.pdf. Accessed 31 May 2013.

Download references

Conflict of interest

Masato Kasuga has received research grants from Drug Company Daiichi Sankyo Co., Ltd., Kohjiro Ueki has received speaker honoraria from Drug Companies Boehringer Ingelheim, Eli Lilly Japan, MSD, Novartis Pharma and Takeda Pharmaceutical Company Limited, research grants from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., MSD, Novartis Pharma, Sanofi and Takeda Pharmaceutical Company Limited, scholarship grants from Astellas Pharma Inc., Boehringer Ingelheim, Daiichi Sankyo Co., Ltd., Eli Lilly Japan, Mitsubishi Tanabe Pharma, MSD, Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Sanofi and Takeda Pharmaceutical Company Limited, Mitsuhiko Noda has received speaker honoraria from Drug Companies Daiichi Sankyo Co., Ltd. and Dainippon Sumitomo Pharma Co., Ltd., and Kohzoh Imai has received research grants from Drug Companies Chugai Pharmaceutical Co., Ltd and Daiichi Sankyo Co., Ltd., and scholarship grants from Chugai Pharmaceutical Co., Ltd. Naoko Tajima, Ken Ohashi, Hiroshi Noto, Atsushi Goto, Wataru Ogawa, Ryuichi Sakai, Nobuyuki Hamajima, Hitoshi Nakagama, Kazuo Tajima, Shoichiro Tsugane and Kohei Miyazono have no conflict of interest.

Author information

Authors and Affiliations

  1. Jikei University School of Medicine, Tokyo, Japan

    Naoko Tajima

  2. National Center for Global Health and Medicine, Tokyo, Japan

    Masato Kasuga, Mitsuhiko Noda, Hiroshi Noto & Atsushi Goto

  3. Department of General Internal Medicine, Dentistry, and Oncologic Emergencies, National Cancer Center Hospital, Tokyo, Japan

    Ken Ohashi

  4. Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

    Kohjiro Ueki

  5. Department of Molecular Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

    Kohei Miyazono

  6. Department of Public Health and Occupational Medicine, Mie University Graduate School of Medicine, Tsu, Japan

    Kazuo Tajima

  7. National Cancer Center Research Institute, Tokyo, Japan

    Hitoshi Nakagama

  8. National Cancer Center, Tokyo, Japan

    Shoichiro Tsugane

  9. Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Nobuyuki Hamajima

  10. Division of Metastasis and Invasion Signaling, National Cancer Center Research Institute, Tokyo, Japan

    Ryuichi Sakai

  11. Center for Antibody and Vaccine Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    Kohzoh Imai

  12. Kobe University Graduate School of Medicine, Kobe, Japan

    Wataru Ogawa

Authors
  1. Masato Kasuga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kohjiro Ueki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoko Tajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mitsuhiko Noda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ken Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Noto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Atsushi Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wataru Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ryuichi Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shoichiro Tsugane
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Nobuyuki Hamajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hitoshi Nakagama
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kazuo Tajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Kohei Miyazono
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Kohzoh Imai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masato Kasuga.

Additional information

In 2013, the Japan Diabetes Society established The Japan Diabetes Society/the Japanese Cancer Association (JDS/JCA) Joint Committee on Diabetes and Cancer, which published the final committee report in Japanese [1]. This is the English version of that report.

This article has been jointly published in Diabetology International and Cancer Science (doi:10.1111/cas.12203 ) by the Japan Diabetes Society and the Japanese Cancer Association.

Appendix

Appendix

The following authors are members of the Japan Diabetes Society: Masato Kasuga, Kohjiro Ueki, Naoko Tajima, Mitsuhiko Noda, and Ken Ohashi.

Editorial Collaborators: Hiroshi Noto, Atsushi Goto, and Wataru Ogawa.

The following authors are members of the Japanese Cancer Association: Ryuichi Sakai, Shoichiro Tsugane, Nobuyuki Hamajima, Hitoshi Nakagama, Kazuo Tajima, Kohei Miyazono, and Kohzoh Imai.

About this article

Cite this article

Kasuga, M., Ueki, K., Tajima, N. et al. Report of the JDS/JCA Joint Committee on Diabetes and Cancer. Diabetol Int 4, 81–96 (2013). https://doi.org/10.1007/s13340-013-0121-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-013-0121-3

Keywords

Search

Navigation